Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 4;12(13):1778.
doi: 10.3390/cells12131778.

Role of CD93 in Health and Disease

Giovanni Tossetta  1 , Federica Piani  2   3 , Claudio Borghi  2   3 , Daniela Marzioni  1
Affiliations
Review

Role of CD93 in Health and Disease

Giovanni Tossetta et al. Cells. .

Abstract

CD93 (also known as complement protein 1 q subcomponent receptor C1qR1 or C1qRp), is a transmembrane glycoprotein encoded by a gene located on 20p11.21 and composed of 652 amino acids. CD93 can be present in two forms: soluble (sCD93) and membrane-bound (CD93). CD93 is mainly expressed on endothelial cells, where it plays a key role in promoting angiogenesis both in physiology and disease, such as age-related macular degeneration and tumor angiogenesis. In fact, CD93 is highly expressed in tumor-associated vessels and its presence correlates with a poor prognosis, poor immunotherapy response, immune cell infiltration and high tumor, node and metastasis (TNM) stage in many cancer types. CD93 is also expressed in hematopoietic stem cells, cytotrophoblast cells, platelets and many immune cells, i.e., monocytes, neutrophils, B cells and natural killer (NK) cells. Accordingly, CD93 is involved in modulating important inflammatory-associated diseases including systemic sclerosis and neuroinflammation. Finally, CD93 plays a role in cardiovascular disease development and progression. In this article, we reviewed the current literature regarding the role of CD93 in modulating angiogenesis, inflammation and tumor growth in order to understand where this glycoprotein could be a potential therapeutic target and could modify the outcome of the abovementioned pathologies.

Keywords: AMD; C1q; C1qR1; C1qRp; CD93; SNP; angiogenesis; cancer; inflammation; polymorphism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Localization of CD93 domains. Y = tyrosine.
Figure 2
Figure 2
Summary of CD93 functions in health and diseases.
Figure 3
Figure 3
Proteins involved in CD93-mediated cytoskeleton remodeling (A) and proteins interacting with CD93 (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McGreal E.P., Ikewaki N., Akatsu H., Morgan B.P., Gasque P. Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q. J. Immunol. 2002;168:5222–5232. doi: 10.4049/jimmunol.168.10.5222. - DOI - PubMed
    1. Khan K.A., McMurray J.L., Mohammed F., Bicknell R. C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation. FEBS J. 2019;286:3299–3332. doi: 10.1111/febs.14985. - DOI - PMC - PubMed
    1. Borah S., Vasudevan D., Swain R.K. C-type lectin family XIV members and angiogenesis. Oncol. Lett. 2019;18:3954–3962. doi: 10.3892/ol.2019.10760. - DOI - PMC - PubMed
    1. Park M., Tenner A.J. Cell surface expression of C1qRP/CD93 is stabilized by O-glycosylation. J. Cell. Physiol. 2003;196:512–522. doi: 10.1002/jcp.10332. - DOI - PubMed
    1. Nepomuceno R.R., Tenner A.J. C1qRP, the C1q receptor that enhances phagocytosis, is detected specifically in human cells of myeloid lineage, endothelial cells, and platelets. J. Immunol. 1998;160:1929–1935. doi: 10.4049/jimmunol.160.4.1929. - DOI - PubMed